leisure time -WSS

leisure time

author：entertainment 2025-10-02 00:06:29 - browse：6

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： 4 missing after record

WSS

Donald Trump's relentless attacks on special counsel Jack Smith

How to protect coverage of PrEP

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Sophia Smith scores twice for US in in 3

#NeedHerScience: shining a light on gender disparities in medicine

#NeedHerScience: shining a light on gender disparities in medicine

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Apple is now the first public company to be valued at $3 trillion

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Duchenne breakthrough therapy leaves behind pioneering families

The response to Covid

Medical records are filled with copy

Disclosing genetic information: not as worrisome as once feared

Activists slam private health insurers over coverage restrictions

Novartis develops a rapidly manufactured CAR

Moonlake's readout produced a cash windfall. Risks remain

The science behind Janet Jackson's pregnancy at 49

leisure time

Do masks work? RCTs can't tell us

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

How a key Senate committee is planning to regulate PBMs

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

Transgender women dream of pregnancy via uterus transplants

With FDA staff opposed to Sarepta therapy, top official intervened

Wikipedia

Wikipedia

hotspot

Wikipedia